About this trial

This observational study investigates the use of Esketamine Intranasal Spray in patients with Treatment-Resistant Depression in Real-World Settings. The study aims to evaluate the clinical outcomes, including efficacy and safety, of esketamine treatment. It also explores predictors of treatment response, focusing on biological pathways such as genetics, neuroimaging, and psychophysical measures. Additionally, the study examines how esketamine impacts patients' life functioning, including social and occupational aspects. The goal is to better understand who benefits most from esketamine and how it affects daily life, to improve personalized care for patients with difficult-to-treat depression.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Esketamine (Intranasal Spray)

Treatment groups

No treatment groups listed

Locations

5
Csm Dds 816158, GenovaGe, Italy
Ospedale Policlinico San Martino16132, GenovaGe, Italy
Università di Chieti66100, Chieti Italy
ASST Fatebenefratelli Sacco20157, Milan Italy

Sponsors and collaborators

Riccardo Guglielmo

Lead sponsor

Universita degli Studi di Genova

Sponsor institution